Search Results

Displaying Results 1-1 of 1 "'URGN'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.

Aug 20, 2026, 07:05 ET IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

announced an equity investment agreement and a strategic Option and Research License Agreement (the Option Agreement) with UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. In a related

More news about: IntraGel Therapeutics

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.